2013-2016年河南中医药大学第一附属医院门诊药房口服降糖药应用分析

目的：了解河南中医药大学第一附属医院（以下简称“我院”）门诊药房口服降糖药的应用情况。方法：采用金额排序和限定日剂量分析方法,对2013—2016年我院门诊药房口服降糖药的品种、销售金额、用药频度和限定日费用等进行统计分析。结果：2013—2016年我院各类口服降糖药的销售金额相对稳定,其中α-葡萄糖苷酶抑制剂和磺酰脲类药物的销售金额各占近1/3的份额。4年来,二甲双胍的用药频度排序均居第1位;格列齐特用药频度增长较快,2015年其用药频度排序超过阿卡波糖,居第2位;格列奈类药物和新型降糖药二肽基肽酶-4抑制剂的使用量较小,噻唑烷二酮类药物的使用量最小。结论：我院门诊糖尿病患者对二甲双胍、格列...

Full description

Saved in:
Bibliographic Details
Published in中国医院用药评价与分析 Vol. 17; no. 4; pp. 537 - 539
Main Author 樊鑫
Format Journal Article
LanguageChinese
Published 河南中医药大学第一附属医院药学部,河南 郑州,450000 2017
Subjects
口服降糖药
用药频度
销售金额
限定日费用
DDDs
DDC
口服降糖药
Oral hypoglycemic drugs
销售金额
限定日费用
用药频度
Consumption sum
Online AccessGet full text
ISSN1672-2124
DOI10.14009/j.issn.1672-2124.2017.04.040

Cover

More Information
Summary:目的：了解河南中医药大学第一附属医院（以下简称“我院”）门诊药房口服降糖药的应用情况。方法：采用金额排序和限定日剂量分析方法,对2013—2016年我院门诊药房口服降糖药的品种、销售金额、用药频度和限定日费用等进行统计分析。结果：2013—2016年我院各类口服降糖药的销售金额相对稳定,其中α-葡萄糖苷酶抑制剂和磺酰脲类药物的销售金额各占近1/3的份额。4年来,二甲双胍的用药频度排序均居第1位;格列齐特用药频度增长较快,2015年其用药频度排序超过阿卡波糖,居第2位;格列奈类药物和新型降糖药二肽基肽酶-4抑制剂的使用量较小,噻唑烷二酮类药物的使用量最小。结论：我院门诊糖尿病患者对二甲双胍、格列齐特和阿卡波糖的选择倾向性较大,上述药物居主导地位,与《中国2型糖尿病指南》（2013版）的要求基本相符。格列奈类药物及新型降糖药二肽基肽酶-4抑制剂等未能得到广泛推广。
Bibliography:OBJECTIVE ：To investigate the application status of oral hypoglycemic drugs in outpatient pharmacy of the First Affiliated Hospital of Henan University （hereinafter referred to as ＂ our hospital＂） during 2013-2016. METHODS： Consumption sum ranking and defined daily dose system （DDDs） methods were adopted, statistical analysis was conducted on the application data of oral hypoglycemic drugs in terms of categories, consumption sum, DDDs and defined daily cost （ DDC）, ect. RESULTS ： The consumption sum of differet~t kinds of oral hypoglycemic drugs were stable during 2013-2016, among which the consumption sum of a-glucosidase inhibitor and sulfonylurea accounted almost 1/3. For four years, the medication frequence ranking of metformin took the lead. The medication frequence of gliclazide were in an increasing trend, the ranking of which dominated the second place and over acarbose in 2015. The consumption amount of glinides andnew antidiabetic drugs of DPP-4 were small, and TZDS drugs was the least. CONCLUSIONS
ISSN:1672-2124
DOI:10.14009/j.issn.1672-2124.2017.04.040